Clearside Biomedical, Inc. (NASDAQ:CLSD) Files An 8-K Other Events
Item 8.01 Other Items.
On August 22, 2019, Clearside Biomedical, Inc. (the “Company”) issued a press release providing an update regarding the status of the Company’s 505(b)(2) New Drug Application with the U.S. Food and Drug Administration for the Company’s product candidate, XIPERETM, for the treatment of macular edema associated with uveitis. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Clearside Biomedical, Inc. Exhibit
EX-99.1 2 clsd-ex991_6.htm EX-99.1 clsd-ex991_6.htm Exhibit 99.1 Clearside Biomedical Provides New Drug Application Update for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) ALPHARETTA,…
To view the full exhibit click here
About Clearside Biomedical, Inc. (NASDAQ:CLSD)
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.
